Metabolism and biological production of resolvins derived from docosapentaenoic acid (DPAn-6)

Bindi Dangi, Marcus Obeng, Julie M Nauroth, Gloria Chung, Eileen Bailey-Hall, Todd Hallenbeck, Linda M. Arterburn

Research output: Contribution to journalArticle

Abstract

17S-HDPAn-6 (17S-hydroxydocosa-4Z,7Z,10Z,13Z,15E-pentaenoic acid) and 10S,17S-HDPAn-6 (10S,17S-dihydroxydocosa-4Z,7Z,11E,13Z,15E-pentaenoic acid) are potent anti-inflammatory resolvins derived from DPAn-6 (docosapentaenoic acid n-6) and are analogous in structure and action to DHA (docosahexaenoic acid)-derived resolvins. These resolvins have proven to be potential drug candidates, albeit with therapeutic profiles that need optimization. The main objectives of this study were to evaluate key features of DPAn-6 derived resolvins that are important for therapeutic efficacy, demonstrate that these DPAn-6 resolvins could be produced naturally, and could therefore have physiological significance. Here we demonstrate biological production, examine pharmacokinetic profiles and identify key routes of metabolic inactivation of DPAn-6 derived resolvins. We compare their metabolic stability to a known resolvin, 17S-HDHA (17S-hydroxydocosa-4Z,7Z,10Z,13Z,15E,19Z-hexaenoic acid) and show that order of their stabilities is 10S,17S-HDPAn-6 > 17S-HDPAn-6 > 17S-HDHA. We show that both these compounds are not strong inhibitors of cytochrome-P450 enzymes. We evaluate activity of compounds in the delayed-type hypersensitivity model, results of which show that compounds need optimization for enhanced duration and magnitude of action. Analysis of the metabolic stability and identification of metabolites of these compounds could play an important role in the design of better analogs with longer durations of action and hence better efficacy.

Original languageEnglish (US)
Pages (from-to)251-260
Number of pages10
JournalBiochemical Pharmacology
Volume79
Issue number2
DOIs
StatePublished - Jan 15 2010
Externally publishedYes

Fingerprint

Metabolism
Cytochrome P-450 Enzyme System
Acids
Pharmacokinetics
Docosahexaenoic Acids
Delayed Hypersensitivity
Metabolites
Anti-Inflammatory Agents
docosapentaenoic acid
Therapeutics
Pharmaceutical Preparations

Keywords

  • Anti-inflammatory
  • Metabolite
  • Oxylipin
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Metabolism and biological production of resolvins derived from docosapentaenoic acid (DPAn-6). / Dangi, Bindi; Obeng, Marcus; Nauroth, Julie M; Chung, Gloria; Bailey-Hall, Eileen; Hallenbeck, Todd; Arterburn, Linda M.

In: Biochemical Pharmacology, Vol. 79, No. 2, 15.01.2010, p. 251-260.

Research output: Contribution to journalArticle

Dangi, B, Obeng, M, Nauroth, JM, Chung, G, Bailey-Hall, E, Hallenbeck, T & Arterburn, LM 2010, 'Metabolism and biological production of resolvins derived from docosapentaenoic acid (DPAn-6)', Biochemical Pharmacology, vol. 79, no. 2, pp. 251-260. https://doi.org/10.1016/j.bcp.2009.08.001
Dangi, Bindi ; Obeng, Marcus ; Nauroth, Julie M ; Chung, Gloria ; Bailey-Hall, Eileen ; Hallenbeck, Todd ; Arterburn, Linda M. / Metabolism and biological production of resolvins derived from docosapentaenoic acid (DPAn-6). In: Biochemical Pharmacology. 2010 ; Vol. 79, No. 2. pp. 251-260.
@article{b5b7ac49e59944ebab5497d37112c395,
title = "Metabolism and biological production of resolvins derived from docosapentaenoic acid (DPAn-6)",
abstract = "17S-HDPAn-6 (17S-hydroxydocosa-4Z,7Z,10Z,13Z,15E-pentaenoic acid) and 10S,17S-HDPAn-6 (10S,17S-dihydroxydocosa-4Z,7Z,11E,13Z,15E-pentaenoic acid) are potent anti-inflammatory resolvins derived from DPAn-6 (docosapentaenoic acid n-6) and are analogous in structure and action to DHA (docosahexaenoic acid)-derived resolvins. These resolvins have proven to be potential drug candidates, albeit with therapeutic profiles that need optimization. The main objectives of this study were to evaluate key features of DPAn-6 derived resolvins that are important for therapeutic efficacy, demonstrate that these DPAn-6 resolvins could be produced naturally, and could therefore have physiological significance. Here we demonstrate biological production, examine pharmacokinetic profiles and identify key routes of metabolic inactivation of DPAn-6 derived resolvins. We compare their metabolic stability to a known resolvin, 17S-HDHA (17S-hydroxydocosa-4Z,7Z,10Z,13Z,15E,19Z-hexaenoic acid) and show that order of their stabilities is 10S,17S-HDPAn-6 > 17S-HDPAn-6 > 17S-HDHA. We show that both these compounds are not strong inhibitors of cytochrome-P450 enzymes. We evaluate activity of compounds in the delayed-type hypersensitivity model, results of which show that compounds need optimization for enhanced duration and magnitude of action. Analysis of the metabolic stability and identification of metabolites of these compounds could play an important role in the design of better analogs with longer durations of action and hence better efficacy.",
keywords = "Anti-inflammatory, Metabolite, Oxylipin, Pharmacokinetics",
author = "Bindi Dangi and Marcus Obeng and Nauroth, {Julie M} and Gloria Chung and Eileen Bailey-Hall and Todd Hallenbeck and Arterburn, {Linda M.}",
year = "2010",
month = "1",
day = "15",
doi = "10.1016/j.bcp.2009.08.001",
language = "English (US)",
volume = "79",
pages = "251--260",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Metabolism and biological production of resolvins derived from docosapentaenoic acid (DPAn-6)

AU - Dangi, Bindi

AU - Obeng, Marcus

AU - Nauroth, Julie M

AU - Chung, Gloria

AU - Bailey-Hall, Eileen

AU - Hallenbeck, Todd

AU - Arterburn, Linda M.

PY - 2010/1/15

Y1 - 2010/1/15

N2 - 17S-HDPAn-6 (17S-hydroxydocosa-4Z,7Z,10Z,13Z,15E-pentaenoic acid) and 10S,17S-HDPAn-6 (10S,17S-dihydroxydocosa-4Z,7Z,11E,13Z,15E-pentaenoic acid) are potent anti-inflammatory resolvins derived from DPAn-6 (docosapentaenoic acid n-6) and are analogous in structure and action to DHA (docosahexaenoic acid)-derived resolvins. These resolvins have proven to be potential drug candidates, albeit with therapeutic profiles that need optimization. The main objectives of this study were to evaluate key features of DPAn-6 derived resolvins that are important for therapeutic efficacy, demonstrate that these DPAn-6 resolvins could be produced naturally, and could therefore have physiological significance. Here we demonstrate biological production, examine pharmacokinetic profiles and identify key routes of metabolic inactivation of DPAn-6 derived resolvins. We compare their metabolic stability to a known resolvin, 17S-HDHA (17S-hydroxydocosa-4Z,7Z,10Z,13Z,15E,19Z-hexaenoic acid) and show that order of their stabilities is 10S,17S-HDPAn-6 > 17S-HDPAn-6 > 17S-HDHA. We show that both these compounds are not strong inhibitors of cytochrome-P450 enzymes. We evaluate activity of compounds in the delayed-type hypersensitivity model, results of which show that compounds need optimization for enhanced duration and magnitude of action. Analysis of the metabolic stability and identification of metabolites of these compounds could play an important role in the design of better analogs with longer durations of action and hence better efficacy.

AB - 17S-HDPAn-6 (17S-hydroxydocosa-4Z,7Z,10Z,13Z,15E-pentaenoic acid) and 10S,17S-HDPAn-6 (10S,17S-dihydroxydocosa-4Z,7Z,11E,13Z,15E-pentaenoic acid) are potent anti-inflammatory resolvins derived from DPAn-6 (docosapentaenoic acid n-6) and are analogous in structure and action to DHA (docosahexaenoic acid)-derived resolvins. These resolvins have proven to be potential drug candidates, albeit with therapeutic profiles that need optimization. The main objectives of this study were to evaluate key features of DPAn-6 derived resolvins that are important for therapeutic efficacy, demonstrate that these DPAn-6 resolvins could be produced naturally, and could therefore have physiological significance. Here we demonstrate biological production, examine pharmacokinetic profiles and identify key routes of metabolic inactivation of DPAn-6 derived resolvins. We compare their metabolic stability to a known resolvin, 17S-HDHA (17S-hydroxydocosa-4Z,7Z,10Z,13Z,15E,19Z-hexaenoic acid) and show that order of their stabilities is 10S,17S-HDPAn-6 > 17S-HDPAn-6 > 17S-HDHA. We show that both these compounds are not strong inhibitors of cytochrome-P450 enzymes. We evaluate activity of compounds in the delayed-type hypersensitivity model, results of which show that compounds need optimization for enhanced duration and magnitude of action. Analysis of the metabolic stability and identification of metabolites of these compounds could play an important role in the design of better analogs with longer durations of action and hence better efficacy.

KW - Anti-inflammatory

KW - Metabolite

KW - Oxylipin

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=71749111455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71749111455&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2009.08.001

DO - 10.1016/j.bcp.2009.08.001

M3 - Article

C2 - 19679107

AN - SCOPUS:71749111455

VL - 79

SP - 251

EP - 260

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 2

ER -